Journals / MN Kardiyoloji / 2010 / Cilt: 17 - Sayı: 3

Association of serum catalase enzyme activity and the presence of ischemic and idiopathic dilated cardiomyopathy

Serum katalaz enzim aktivitesi ile iskemik ve idyopatik dilate kardiyomiyopati varlığının ilişkisi

Pages
172–179
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The results of this study showed that TAK and TOK has not changed significantly but serum catalase activity is significantly decreased in the ischemic and idiopathic dilated cardiomyopathy compared to controls.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Oxidant and antioxidant parameters are important in various heart diseases.
📊
Key Findings & Data:In the etiopathogenesis of cardiomyopathies (KMP), it had been shown increased oxidant substances and reduced various antioxidant substances and enzymes.
💡
Conclusion & Impact:Conclusion: The results of this study showed that TAK and TOK has not changed significantly but serum catalase activity is significantly decreased in the ischemic and idiopathic dilated cardiomyopathy compared to controls.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Oxidant and antioxidant parameters are important in various heart diseases. In the etiopathogenesis of cardiomyopathies (KMP), it had been shown increased oxidant substances and reduced various antioxidant substances and enzymes. The aim of our study is to determine total antioxidant capacity (TAK), total oxidant capacity (TOK), oxidative stress index (OSI) and serum catalase activities among patients with idiopathic and ischemic KMP and healthy volunteers. Material and Method: Patients with low ejection fraction and larger left ventricle on echocardiography were divided two groups according to the presence of ischemic heart disease as ischemic (Group 1, n=21) and idiopathic KMP (Group 2, n=21). Twenty-five healthy volunteers were identified as control group (Group 3). Anthropometric and biochemical data of all individuals, presence of hypertension, diabetes mellitus, dyslipidemia, drug and smoking history were recorded. TAK and TOK values were measured by Erel&#8217;s methods and serum catalase activity by Goth's calorimetric method in the previously collected and stored serum samples. TOK / TAK ratio was considered as OSI. Results: Anthropometric and biochemical parameters, statin use was not different among the groups. Acetylsalicylic acid, angiotensin-converting enzyme inhibitors, and beta-blocker use had significant difference among the groups (p<0.05). Echocardiographic parameters were similar between Groups 1 and 2 but both groups were significantly different than group 3 (p<0.05). TAK, TOK and OSI were not significantly different among the groups. Catalase activity was not significantly different between groups 1 and 2 (p>0.05), but it was statistically significantly different in both KMP groups than in group 3 (p<0.05). Conclusion: The results of this study showed that TAK and TOK has not changed significantly but serum catalase activity is significantly decreased in the ischemic and idiopathic dilated cardiomyopathy compared to controls.

Özet

Amaç: Kalp hastalıklarında oksidan ve antioksidan parametreler önemli yer tutar. Kardiyomiyopati (KMP) etiyopatogenezinde çeşitli oksidan maddelerin arttığı antioksidan maddelerin ve enzimlerin de azaldığı gösterilmiştir. Amacımız serum total antioksidan kapasite (TAK), total oksidan kapasite (TOK), oksidatif stres indeksi (OSİ) ve katalaz enzim aktivitelerinin idyopatik ve iskemik KMP hastaları ile sağlıklı gönüllüler arasında nasıl değiştiğini araştırmaktı. Gereç ve Yöntem: Ekokardiyografide kardiyomiyopati (düşük ejeksiyon fraksiyonu ve geniş sol ventrikül) olan hastalar iskemik kalp hastalığı varlığına göre iskemik (Grup 1; n=21) ve idyopatik KMP (Grup 2; n=29) grubu olmak üzere iki gruba ayrıldı. 25 sağlıklı gönüllü olgu kontrol grubu olarak belirlendi (Grup 3). Bütün bireylerin antropometrik verileri ve biyokimyasal verileri ile hipertansiyon, diabetes mellitus, dislipidemi varlığı, ilaç ve sigara kullanım öyküleri kaydedildi. Alınıp uygun ortamda saklanan serum örneklerinden serum katalaz aktivitesi Goth’un kalorimetrik yöntemi, TAK ve TOK değerleri Erel yöntemi ile ölçüldü. OSİ’yi bulmak için TOK ile TAK oranlandı. Bulgular: Gruplar arasında antropometrik ve biyokimyasal parametreler açısından ve statin kullanımı yönünden fark yoktu. Asetilsalisik asit, anjiyotensin konverting enzim inhibitörü ve beta bloker kullanımı açısından anlamlı fark vardı (p<0,05). Ekokardiyografik parametreler Grup 1 ve 2 arasında benzer iken her iki grubun grup 3’le arasında anlamlı fark vardı (p<0,05). TAK, TOK, OSİ yönünden gruplar arasında anlamlı fark yoktu. Katalaz aktivitesi grup 1 ve 2 arasında farklı değildi ancak KMP grupları ile grup 3 grubu arasında anlamlı fark vardı (p<0,05). Sonuç: Bu çalışmanın sonuçları iskemik ve idyopatik dilate KMP hastalarında kontrollere göre TOK ve TAK belirgin olarak değişmese de serum katalaz aktivitesinin belirgin olarak azaldığını göstermektedir.

🔖

Cite This Article

SEZEN, Y., GÜNTEKİN, Ü., YILDIZ, A., DEMİRBAĞ, R., BAŞ, M. M., KÜÇÜKDURMAZ, Z., SEZEN, H., BÜYÜKASLAN, H., BÜYÜKHATİPOĞLU, H., TAŞKIN, A., ÇELİK, H., AKSOY, N. (2010). Association of serum catalase enzyme activity and the presence of ischemic and idiopathic dilated cardiomyopathy. MN Kardiyoloji, Cilt: 17 - Sayı: 3, 172–179. https://ajindex.com/articles/297497

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Nishiyama K, Tsutamoto T, Yamaji M, Kawahara C, Yamamoto T, Fujii M, et al. Dose-dependent prognostic effect of carvedilol in patients with chronic heart failurespecial reference to transcardiac [corrected] gradient of norepinephrine. Circ J 2009;73:2270-5
  2. Demirbağ R, Yılmaz R, Erel O, Gültekin U, Asci D, Elbasan Z. The relationship between potency of oxidative stress and severity of dilated cardiomyopathy. Can J Cardiol 2005;2:851-5
  3. Fatjó F, Fernández-Solà J, Lluís M, Elena M, Badía E, Sacanella E, et al. Myocardial antioxidant status in chronic alcoholism. Alcohol Clin Exp Res 2005;29:864-70
  4. Bäumer AT, Flesch M, Wang X, Shen Q, Feuerstein GZ, Böhm M. Antioxidative enzymes in human hearts with idiopathic dilated cardiomyopathy. J Mol Cell Cardiol 2000;32:121-30
  5. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97
  6. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004; 37:112-9
  7. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005; 38:1103- 11
  8. Kosecik M, Erel O, Sevinc E, Selek S. Increased oxidative stress in children exposed to passive smoking. Int J Cardiol 2005; 100:61-4
  9. Góth L. A simple method for determination of serum cata lase activity and revision of reference range. Clin Chim Acta 1991; 196:143-51
  10. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Commit - tee on Standards, Subcommittee on Quanti ta tion of Two-Dimensional Echocardiograms. J Am Soc Echocar - diogr 1989; 2:358-67
  11. Schiller NB, Acquatella H, Ports TA, Drew D, Goerke J, Ringertz H, et al. Left ventricular volume from paired biplane two-dimensional echocardiography. Circulation 1979;60:547-55
  12. Halliwell B, Aruoma OI. DNA damage by oxygen- derived species. Its mechanism and measurement in mammalian systems. FEBS Lett 1991; 281:9-19
  13. Halliwell B. Oxidative stress and cancer: have we moved forward? Biochem J 2007; 401:1-11
  14. Cimen MY, Cimen OB, Kacmaz M, Oztürk HS, Yorgancioğlu R, Durak I. Oxidant/antioxidant status of the erythrocytes from patients with rheumatoid arthritis. Clin Rheumatol